Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MT-7117 in Erythropoietic Protoporphyria or X-Linked Protoporphyria
jRCT2031230656Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) comparing MT-7117 with Placebo (2 arms). Primary endpoint: Change from baseline in average daily sunlight exposure time to first prodromal symptom at Week 16. Started Apr 2024; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on jRCT2031230656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230656.